3PBIOVIAN Drives a Pioneering Project with the Navarre Ecosystem to Improve the Efficacy and Accessibility of CAR-T Therapies
A consortium formed by the Clínica Universidad de Navarra, the Hospital Universitario de Navarra, the University of Navarra, the research centers FIMA and Navarrabiomed, and the technology companies 3PBIOVIAN, Eversens, and Nasertic is developing an ambitious scientific and technological project to advance the efficacy, safety, and accessibility of CAR-T cell–based therapies.
As a CDMO specialized in process development and the production of biologics and advanced therapies, 3PBIOVIAN brings its expertise in GMP development and manufacturing, strengthening the consortium’s ability to translate scientific advances into scalable therapeutic solutions with real potential impact for patients.
The project aims to deepen the understanding of the biological mechanisms that explain why CAR-T therapies work in some cases and fail in others, with the goal of enabling the design of new, more effective drugs with lower toxicity and greater affordability.
To achieve this, the research team is using artificial intelligence (AI) and machine learning applied to multi-omic data analysis to identify resistance mechanisms to CAR-T therapies. In addition, high-throughput sequencing and gene-editing technologies are being employed to study and optimize therapeutic cells with unprecedented precision.
The project enables the transformation of scientific knowledge into robust, reproducible development and manufacturing processes. At 3PBIOVIAN, the Advanced Therapies Development and Production team is working to ensure that future CAR-T treatments are more effective, safe, and accessible, thereby strengthening the consortium’s capacity to bring these innovations into clinical practice.
The DIAMANTE project (File 0011-1411-2023-000105) is funded by the Government of Navarre through the 2023–2026 call for strategic R&D projects (Resolution 72E/2023, dated March 31, from the Directorate General of Industry, Energy, and Strategic Projects S4).
